Overview
Peptides are restricted in Japan under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (the PMD Act, commonly called Yakkiho), which is enforced by the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA). Japan has no separate 'peptide schedule'; instead, any peptide intended for human use is treated as a pharmaceutical that requires MHLW approval before it can be manufactured, imported for business, sold, or advertised domestically. Approved GLP-1 peptide drugs like Wegovy (semaglutide) and diabetes peptide medicines are dispensed only through licensed prescribers, while unapproved compounds such as BPC-157 or TB-500 fall into the 'unapproved drug' (無承認無許可医薬品) category that MHLW actively warns about. Individuals can bring in only small personal-use quantities of medicines, generally needing an import confirmation certificate, and reselling personally imported peptides is prohibited.
Key Points
- Japan regulates all peptides intended for human use as pharmaceuticals under the PMD Act, requiring Ministry of Health, Labour and Welfare (MHLW) approval and licensing before any such product may be manufactured, imported for business, sold, or advertised. [1]
- MHLW approved the GLP-1 peptide drug Wegovy (semaglutide) for obesity in Japan in 2023, but restricted its use to patients with a BMI of at least 27 who also have hypertension, dyslipidemia, or type 2 diabetes, or a BMI of at least 35. [2]
- Peptides with no Japanese regulatory approval, including research peptides like BPC-157 and TB-500, are treated in Japan as 'unapproved, unlicensed drugs' (無承認無許可医薬品) that cannot lawfully be sold or advertised domestically because their quality, efficacy, and safety have not been confirmed under the PMD Act. [3]
- A person can personally bring or import peptides and other medicines into Japan for their own use only in limited quantities, and doing so generally requires an import confirmation certificate (Yunyu Kakunin-sho, formerly known as Yakkan Shoumei) issued by a Regional Bureau of Health and Welfare, with special customs-only clearance available for small amounts. [4]
- Japan's MHLW states that personal drug importation exists to accommodate people continuing overseas drug treatment or travelers carrying their own medicine, and importing a product to sell or give to someone else is not permitted even under a personal-import certificate. [5]
- For any medicine, including peptides, that MHLW judges could cause serious health harm if used without a doctor's involvement, MHLW does not allow personal importation by ordinary individuals regardless of quantity unless a prescription can be confirmed. [6]
- MHLW has documented and publicized cases of health harm in Japan from personally imported unapproved drugs, including a 2002 report of liver injury linked to unapproved weight-loss products imported from China, illustrating the enforcement and public-health rationale behind Japan's unapproved-drug rules. [7]
- Reselling or transferring personally imported peptides or other medicines to another person is prohibited in Japan even when the original import itself was lawful for personal use. [4]